65,437 trials
Type 2 Diabetes
Primary: Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy — 87…
Chronic Kidney Disease · Chronic Renal Disease
Primary: Effect of Increased Dialysate Flow Rate on KoA for Urea Between 4 Dialyzers With Different Membrane Packing Densities. — 844; 763; 770; 798 KoA for urea (mL/min)
HIV Infections · Pregnancy Related
Primary: Satisfaction With HIV Testing Experience (O'Connor Decisional Conflict Scale) — 16.0; 19.9 scores on scale
Fibromyalgia
Primary: Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale. — -3.69; -3.08; -1.97 Scores on a scale
IgA Nephropathy
Primary: Change in Renal Function as Measured With eGFR — 68.9; 73.2 eGFR(min/ml)
Stress Urinary Incontinence
Primary: Change From Baseline in Opening Urethral Pressure (OUP) at Day 7 — 49.86; 49.86; 49.86; 47.92 centimeter of water (cmH2O) — p=0.4907
Uterine Fibroids · Leiomyoma · Menorrhagia
Primary: Number of Adverse Events — 1 Participants
Parkinson's Disease
Primary: Tolerability of Isradipine Based on the Number of Participants That Complete the Study — 25 Participants
Osteoporosis
Primary: Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Intent-to-Treat…
Prostatic Hyperplasia
Primary: Number of Participants With Clinical Progression — 14; 5 participants — p=0.0128
Barrett Esophagus
Primary: Percentage of Participants With Histological Clearance of Barrett's Metaplasia — 100; 20; 78; 82 Percent of Participants
Erectile Dysfunction · Benign Prostatic Hyperplasia
Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg) — -6.1; -3.8 units on a scale — p=<0.001
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Relapsed Leukemia
Primary: Maximum Tolerated Dose (MTD) in Phase 1 — 0; 0; 0; 0 units on a scale
Acute Respiratory Infections · Acute Rhinosinusitis
Primary: SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3 — 1.12; 1.14 Units on a scale — p=0.83
Sleep Apnea, Obstructive
Primary: Number of Participants With Saturation Pattern Detection (SPD) Indicative of Repetitive Reductions in Air Flow — 4; 0 Participants